Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-10-21
Butterfly Network, Inc.
Butterfly Network sells handheld whole-body ultrasound devices, cloud workflow software, education tools, and partner licensing built around its semiconductor ultrasound platform.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Proof Matters More Than Probe Volume
The upside case is a transition from device seller to regulated imaging workflow hub. The key question is whether partner launches and enterprise attach become durable revenue before bigger incumbents blunt pricing power.

Analysis

Thesis
Butterfly can still produce a 2x-3x equity outcome by 2031 if AI-assisted scanning turns each probe into the front door for governed workflow, education, and partner apps, shifting the business from mostly hardware toward recurring software and licensing before larger imaging vendors close the gap.
Last Economy Alignment
AI should widen handheld ultrasound use because it lowers the skill barrier, and Butterfly controls the regulated scan surface plus cloud workflow. The main check is that larger imaging vendors can still bundle away part of the software upside.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
This is a quality-of-revenue thesis, not just a unit-growth thesis. If Butterfly proves that each probe can pull through workflow software, education, and partner economics, the market can keep valuing it as a platform-like medtech asset even with some multiple compression from today’s speculative level. If that proof stays thin, the upside shrinks fast.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is conversion, not invention. Butterfly already has a real product and improving margins, but the 2031 case requires partner launches, enterprise workflow attach, and home or government expansion to become durable revenue before larger imaging vendors use distribution and bundling to cap pricing power.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.45
AI makes ultrasound easier to use, and this company controls the probe, the app surface, and much of the cloud workflow around the scan. That gives it a shot at owning the trusted checkpoint, but big imaging vendors and regulators can still slow or squeeze it.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$11.17
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case